3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
1
Leukemia
1
Interventions
Carboplatin
36
Cisplatin
32
pembrolizumab
29
Paclitaxel
29
Pemetrexed
22
Gemcitabine
21
Nivolumab
19
Dexamethasone
17
Rituximab
16
Fluorouracil
13
Docetaxel
13
durvalumab
12
Ipilimumab
12
Capecitabine
12
Cyclophosphamide
11
atezolizumab
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Trastuzumab
9
Lenalidomide
9
Doxorubicin
9
Cytarabine
9
Bevacizumab
9
daratumumab
8
Oxaliplatin
8
Bortezomib
8
Vinorelbine
7
Prednisone
7
Leucovorin
7
venetoclax
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
quizartinib
×
Clear all
NCT02668653
2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3
Completed
539 enrolled
20 charts
1 FDA